Press Releases and News

Aphios Awarded Grant for Developing CGMP Process for CBD Using Green Drug Manufacturing Technology
September 16, 2014
Woburn, Mass. − Aphios Corporation today announced that it was awarded Phase I of a Fast Track SBIR grant from the National Institute on Drug Abuse (NIDA), NIH to develop a process for manufacturing cGMP cannabidiol (CBD) using its green drug manufacturing technology.

The primary goal of this research program is to develop a process for manufacturing pharmaceutical grade CBD following current Good Manufacturing Practices (cGMP) of the US FDA for use in clinical trials for Multiple Sclerosis, childhood epilepsy and other CNS indications by the NIH and other researchers. The ready availability of pharmaceutical-grade CBD, manufactured following cGMP guidelines, will facilitate clinical evaluation by NIH investigators and other researchers for epilepsy, MS and other CNS diseases. The developed process will also be utilized for the manufacturing of Δ9-THC, already in use for cancer pain and nausea and AIDS-related cachexia, and other cannabinoids such as cannabigerol (CBG) in development.

According to Dr. Trevor P. Castor, CEO and Principal Investigator on this grant "We believe that CBD can be cost-effectively manufactured from high CBD content Cannabis sativa (hemp) utilizing supercritical fluid technology, and that such a process could also produce other bioactive cannabinoid mixtures for future research and therapeutic use."  Dr. Castor continues, "We propose to manufacture pharmaceutical-grade CBD following cGMP guidelines by utilizing supercritical fluids and near-critical fluids with or without polar co-solvents such as alcohols (SuperFluids™). These fluids are gases such as carbon dioxide which when compressed, exhibit enhanced thermodynamic properties that can be 'fine-tuned' for rapid and selective extraction of bioactive molecules. Products of our critical fluid extraction and purification (CXP) manufacturing technology are free of toxic organic solvents, environmentally friendly and truly 'green.'"

About Aphios Corporation

Aphios Corporation is a clinical stage biotechnology company developing green enabling technology platforms for improving drug discovery, manufacturing, delivery and safety, and enhanced natural therapeutics for health maintenance and disease prevention, and the treatment of cancers and supportive care, infectious diseases such as HIV, and CNS disorders such as Alzheimer's disease and Multiple Sclerosis.

Research reported in this press release is supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number R44DA038932. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.